Educational Session XI. Updates on Liquid Biopsy |
Crystal 2 + Crystal 3 |
Chair : Young Whan Kim (Seoul National Univ., Korea)
Richie Soong (Yong Loo Lin School of Medicine, Singapore)
|
Time |
Topic |
Speaker |
11:00-11:30 |
The Value Proposition of Liquid Biopsies to Precision Medicine |
Richie Soong (Yong Loo Lin School of Medicine, Singapore) |
11:30-12:00 |
Liquid Biopsy Successfully Detects Best Drugs for Treating Lung Cancer  |
James Yang (National Taiwan University Hospital, Taiwan) |
12:00-12:30 |
Extracellular Vesicles(EV)-derived DNA for Liquid Biopsy in Lung Cancer |
Kye Young Lee (Konkuk Univ., Korea) |
Educational Session XII. New Staging |
Crystal 3 |
Chair : Geon Kook Lee (National Cancer Center, Korea)
Shiu-Feng Huang
(Institute of Molecular and Genomic Medicine, Taiwan)
|
Time |
Topic |
Speaker |
11:00-11:30 |
The Clinical Correlation of the 8th AJCC Staging System in Lung Adenocarcinoma Focusing on Early Stage Patients: Taiwan Experience |
Shiu-Feng Huang (Institute of Molecular and Genomic Medicine, Taiwan)
|
11:30-12:00 |
Lung Cancers with Multiple Pulmonary Sites of
Involvement in the Eighth Edition of the TNM Classification |
Hyo Sup Shim (Yonsei Univ., Korea) |
12:00-12:30 |
Clinical Significance of New WHO Classification of Lung Cancer  |
Hironori Ninomiya
(The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Japan)
|
Plenary Session II. Predictive Marker for Immunotherapy Basic Perspective for Immunotherapy in Lung Cancer |
Crystal 1 + Crystal 2 + Crystal 3 |
Chair : Myung Ju Ahn (Sungkyunkwan Univ., Korea) Michael Boyer(Chris O'Brien Lifehouse, Australia)
|
Time |
Topic |
Speaker |
09:00-09:30 |
Basic Perspective for Immunotherapy in Lung Cancer |
Eui Cheol Shin (KAIST, Korea) |
09:30-10:00 |
Clinical Perspective for Current Immunotherapy in NSCLC  |
Michael Boyer (Chris O'Brien Lifehouse, Australia) |
10:00-10:30 |
Beyond PD-l/PD-L1 Inhibitor:
New Targeted Immunotherapy or Combination Therapy |
Tien Hoang (Genentech, USA) |